amlodipine	sildenafil	9	9	false	none	Amlodipine    When sildenafil 100 mg oral was co-administered with amlodipine, 5 mg or 10 mg oral, to hypertensive patients, the mean additional reduction on supine blood pressure was 8 mmHg systolic and 7 mmHg diastolic.  		17767	136411	D017311	C101426
amlodipine	sildenafil	9	9	false	none	Amlodipine    When sildenafil 100 mg oral was co-administered with amlodipine, 5 mg or 10 mg oral, to hypertensive patients, the mean additional reduction on supine blood pressure was 8 mmHg systolic and 7 mmHg diastolic.  		17767	136411	D017311	C101426
amlodipine	Amlodipine	9	9	false	none	Amlodipine    When sildenafil 100 mg oral was co-administered with amlodipine, 5 mg or 10 mg oral, to hypertensive patients, the mean additional reduction on supine blood pressure was 8 mmHg systolic and 7 mmHg diastolic.  		D017311	D017311
REVATIO	ritonavir	1	2	false	none	7 DRUG INTERACTIONS    Nitrates    Concomitant use of REVATIO with nitrates in any form is contraindicated [see Contraindications (4)].  Ritonavir and other Potent CYP3A Inhibitors    Concomitant use of REVATIO with ritonavir and other potent CYP3A inhibitors is not recommended [see Warnings and Precautions (5.3)].  		0	85762	581642	85762
REVATIO	ritonavir	1	2	false	none	7 DRUG INTERACTIONS    Nitrates    Concomitant use of REVATIO with nitrates in any form is contraindicated [see Contraindications (4)].  Ritonavir and other Potent CYP3A Inhibitors    Concomitant use of REVATIO with ritonavir and other potent CYP3A inhibitors is not recommended [see Warnings and Precautions (5.3)].  		0	85762	581642	85762
REVATIO	ritonavir	2	2	false	none	Ritonavir and other Potent CYP3A Inhibitors    Concomitant use of REVATIO with ritonavir and other potent CYP3A inhibitors is not recommended [see Warnings and Precautions (5.3)].  		0	85762	581642	85762
REVATIO	ritonavir	2	2	false	none	Ritonavir and other Potent CYP3A Inhibitors    Concomitant use of REVATIO with ritonavir and other potent CYP3A inhibitors is not recommended [see Warnings and Precautions (5.3)].  		0	85762	581642	85762
REVATIO	ritonavir	3	2	false	none	Ritonavir and other Potent CYP3A Inhibitors    Concomitant use of REVATIO with ritonavir and other potent CYP3A inhibitors is not recommended [see Warnings and Precautions (5.3)].  Alpha-blockers    Use caution when co-administering alpha-blockers with REVATIO because of additive blood pressure-lowering effects [see Warnings and Precautions (5.1)].  		0	85762	581642	85762
REVATIO	ritonavir	3	2	false	none	Ritonavir and other Potent CYP3A Inhibitors    Concomitant use of REVATIO with ritonavir and other potent CYP3A inhibitors is not recommended [see Warnings and Precautions (5.3)].  Alpha-blockers    Use caution when co-administering alpha-blockers with REVATIO because of additive blood pressure-lowering effects [see Warnings and Precautions (5.1)].  		0	85762	581642	85762
REVATIO	Ritonavir	1	2	false	none	7 DRUG INTERACTIONS    Nitrates    Concomitant use of REVATIO with nitrates in any form is contraindicated [see Contraindications (4)].  Ritonavir and other Potent CYP3A Inhibitors    Concomitant use of REVATIO with ritonavir and other potent CYP3A inhibitors is not recommended [see Warnings and Precautions (5.3)].  		0	85762	581642	D019438
REVATIO	Ritonavir	1	2	false	none	7 DRUG INTERACTIONS    Nitrates    Concomitant use of REVATIO with nitrates in any form is contraindicated [see Contraindications (4)].  Ritonavir and other Potent CYP3A Inhibitors    Concomitant use of REVATIO with ritonavir and other potent CYP3A inhibitors is not recommended [see Warnings and Precautions (5.3)].  		0	85762	581642	D019438
REVATIO	Ritonavir	2	2	false	none	Ritonavir and other Potent CYP3A Inhibitors    Concomitant use of REVATIO with ritonavir and other potent CYP3A inhibitors is not recommended [see Warnings and Precautions (5.3)].  		0	85762	581642	D019438
REVATIO	Ritonavir	2	2	false	none	Ritonavir and other Potent CYP3A Inhibitors    Concomitant use of REVATIO with ritonavir and other potent CYP3A inhibitors is not recommended [see Warnings and Precautions (5.3)].  		0	85762	581642	D019438
REVATIO	Ritonavir	3	2	false	none	Ritonavir and other Potent CYP3A Inhibitors    Concomitant use of REVATIO with ritonavir and other potent CYP3A inhibitors is not recommended [see Warnings and Precautions (5.3)].  Alpha-blockers    Use caution when co-administering alpha-blockers with REVATIO because of additive blood pressure-lowering effects [see Warnings and Precautions (5.1)].  		0	85762	581642	D019438
REVATIO	Ritonavir	3	2	false	none	Ritonavir and other Potent CYP3A Inhibitors    Concomitant use of REVATIO with ritonavir and other potent CYP3A inhibitors is not recommended [see Warnings and Precautions (5.3)].  Alpha-blockers    Use caution when co-administering alpha-blockers with REVATIO because of additive blood pressure-lowering effects [see Warnings and Precautions (5.1)].  		0	85762	581642	D019438
REVATIO	sildenafil	2	4	false	none	Ritonavir and other Potent CYP3A Inhibitors    Concomitant use of REVATIO with ritonavir and other potent CYP3A inhibitors is not recommended [see Warnings and Precautions (5.3)].  Alpha-blockers    Use caution when co-administering alpha-blockers with REVATIO because of additive blood pressure-lowering effects [see Warnings and Precautions (5.1)].  In drug-drug interaction studies, sildenafil (25 mg, 50 mg, or 100 mg) and the alpha-blocker doxazosin (4 mg or 8 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy.  		0	136411	581642	C101426
REVATIO	sildenafil	2	4	false	none	Ritonavir and other Potent CYP3A Inhibitors    Concomitant use of REVATIO with ritonavir and other potent CYP3A inhibitors is not recommended [see Warnings and Precautions (5.3)].  Alpha-blockers    Use caution when co-administering alpha-blockers with REVATIO because of additive blood pressure-lowering effects [see Warnings and Precautions (5.1)].  In drug-drug interaction studies, sildenafil (25 mg, 50 mg, or 100 mg) and the alpha-blocker doxazosin (4 mg or 8 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy.  		0	136411	581642	C101426
REVATIO	sildenafil	3	4	false	none	Alpha-blockers    Use caution when co-administering alpha-blockers with REVATIO because of additive blood pressure-lowering effects [see Warnings and Precautions (5.1)].  In drug-drug interaction studies, sildenafil (25 mg, 50 mg, or 100 mg) and the alpha-blocker doxazosin (4 mg or 8 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy.  		0	136411	581642	C101426
REVATIO	sildenafil	3	4	false	none	Alpha-blockers    Use caution when co-administering alpha-blockers with REVATIO because of additive blood pressure-lowering effects [see Warnings and Precautions (5.1)].  In drug-drug interaction studies, sildenafil (25 mg, 50 mg, or 100 mg) and the alpha-blocker doxazosin (4 mg or 8 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy.  		0	136411	581642	C101426
REVATIO	doxazosin	2	4	false	none	Ritonavir and other Potent CYP3A Inhibitors    Concomitant use of REVATIO with ritonavir and other potent CYP3A inhibitors is not recommended [see Warnings and Precautions (5.3)].  Alpha-blockers    Use caution when co-administering alpha-blockers with REVATIO because of additive blood pressure-lowering effects [see Warnings and Precautions (5.1)].  In drug-drug interaction studies, sildenafil (25 mg, 50 mg, or 100 mg) and the alpha-blocker doxazosin (4 mg or 8 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy.  		0	49276	581642	49276
REVATIO	doxazosin	2	4	false	none	Ritonavir and other Potent CYP3A Inhibitors    Concomitant use of REVATIO with ritonavir and other potent CYP3A inhibitors is not recommended [see Warnings and Precautions (5.3)].  Alpha-blockers    Use caution when co-administering alpha-blockers with REVATIO because of additive blood pressure-lowering effects [see Warnings and Precautions (5.1)].  In drug-drug interaction studies, sildenafil (25 mg, 50 mg, or 100 mg) and the alpha-blocker doxazosin (4 mg or 8 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy.  		0	49276	581642	49276
REVATIO	doxazosin	3	4	false	none	Alpha-blockers    Use caution when co-administering alpha-blockers with REVATIO because of additive blood pressure-lowering effects [see Warnings and Precautions (5.1)].  In drug-drug interaction studies, sildenafil (25 mg, 50 mg, or 100 mg) and the alpha-blocker doxazosin (4 mg or 8 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy.  		0	49276	581642	49276
REVATIO	doxazosin	3	4	false	none	Alpha-blockers    Use caution when co-administering alpha-blockers with REVATIO because of additive blood pressure-lowering effects [see Warnings and Precautions (5.1)].  In drug-drug interaction studies, sildenafil (25 mg, 50 mg, or 100 mg) and the alpha-blocker doxazosin (4 mg or 8 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy.  		0	49276	581642	49276
ritonavir	Ritonavir	2	2	false	none	Ritonavir and other Potent CYP3A Inhibitors    Concomitant use of REVATIO with ritonavir and other potent CYP3A inhibitors is not recommended [see Warnings and Precautions (5.3)].  		85762	D019438
ritonavir	sildenafil	2	4	false	none	Ritonavir and other Potent CYP3A Inhibitors    Concomitant use of REVATIO with ritonavir and other potent CYP3A inhibitors is not recommended [see Warnings and Precautions (5.3)].  Alpha-blockers    Use caution when co-administering alpha-blockers with REVATIO because of additive blood pressure-lowering effects [see Warnings and Precautions (5.1)].  In drug-drug interaction studies, sildenafil (25 mg, 50 mg, or 100 mg) and the alpha-blocker doxazosin (4 mg or 8 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy.  		85762	136411	85762	C101426
ritonavir	sildenafil	2	4	false	none	Ritonavir and other Potent CYP3A Inhibitors    Concomitant use of REVATIO with ritonavir and other potent CYP3A inhibitors is not recommended [see Warnings and Precautions (5.3)].  Alpha-blockers    Use caution when co-administering alpha-blockers with REVATIO because of additive blood pressure-lowering effects [see Warnings and Precautions (5.1)].  In drug-drug interaction studies, sildenafil (25 mg, 50 mg, or 100 mg) and the alpha-blocker doxazosin (4 mg or 8 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy.  		85762	136411	85762	C101426
ritonavir	doxazosin	2	4	false	none	Ritonavir and other Potent CYP3A Inhibitors    Concomitant use of REVATIO with ritonavir and other potent CYP3A inhibitors is not recommended [see Warnings and Precautions (5.3)].  Alpha-blockers    Use caution when co-administering alpha-blockers with REVATIO because of additive blood pressure-lowering effects [see Warnings and Precautions (5.1)].  In drug-drug interaction studies, sildenafil (25 mg, 50 mg, or 100 mg) and the alpha-blocker doxazosin (4 mg or 8 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy.  		85762	49276	85762	49276
ritonavir	doxazosin	2	4	false	none	Ritonavir and other Potent CYP3A Inhibitors    Concomitant use of REVATIO with ritonavir and other potent CYP3A inhibitors is not recommended [see Warnings and Precautions (5.3)].  Alpha-blockers    Use caution when co-administering alpha-blockers with REVATIO because of additive blood pressure-lowering effects [see Warnings and Precautions (5.1)].  In drug-drug interaction studies, sildenafil (25 mg, 50 mg, or 100 mg) and the alpha-blocker doxazosin (4 mg or 8 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy.  		85762	49276	85762	49276
Ritonavir	sildenafil	2	4	false	none	Ritonavir and other Potent CYP3A Inhibitors    Concomitant use of REVATIO with ritonavir and other potent CYP3A inhibitors is not recommended [see Warnings and Precautions (5.3)].  Alpha-blockers    Use caution when co-administering alpha-blockers with REVATIO because of additive blood pressure-lowering effects [see Warnings and Precautions (5.1)].  In drug-drug interaction studies, sildenafil (25 mg, 50 mg, or 100 mg) and the alpha-blocker doxazosin (4 mg or 8 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy.  		85762	136411	D019438	C101426
Ritonavir	sildenafil	2	4	false	none	Ritonavir and other Potent CYP3A Inhibitors    Concomitant use of REVATIO with ritonavir and other potent CYP3A inhibitors is not recommended [see Warnings and Precautions (5.3)].  Alpha-blockers    Use caution when co-administering alpha-blockers with REVATIO because of additive blood pressure-lowering effects [see Warnings and Precautions (5.1)].  In drug-drug interaction studies, sildenafil (25 mg, 50 mg, or 100 mg) and the alpha-blocker doxazosin (4 mg or 8 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy.  		85762	136411	D019438	C101426
Ritonavir	doxazosin	2	4	false	none	Ritonavir and other Potent CYP3A Inhibitors    Concomitant use of REVATIO with ritonavir and other potent CYP3A inhibitors is not recommended [see Warnings and Precautions (5.3)].  Alpha-blockers    Use caution when co-administering alpha-blockers with REVATIO because of additive blood pressure-lowering effects [see Warnings and Precautions (5.1)].  In drug-drug interaction studies, sildenafil (25 mg, 50 mg, or 100 mg) and the alpha-blocker doxazosin (4 mg or 8 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy.  		85762	49276	D019438	49276
Ritonavir	doxazosin	2	4	false	none	Ritonavir and other Potent CYP3A Inhibitors    Concomitant use of REVATIO with ritonavir and other potent CYP3A inhibitors is not recommended [see Warnings and Precautions (5.3)].  Alpha-blockers    Use caution when co-administering alpha-blockers with REVATIO because of additive blood pressure-lowering effects [see Warnings and Precautions (5.1)].  In drug-drug interaction studies, sildenafil (25 mg, 50 mg, or 100 mg) and the alpha-blocker doxazosin (4 mg or 8 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy.  		85762	49276	D019438	49276
sildenafil	Amlodipine	9	9	false	none	Amlodipine    When sildenafil 100 mg oral was co-administered with amlodipine, 5 mg or 10 mg oral, to hypertensive patients, the mean additional reduction on supine blood pressure was 8 mmHg systolic and 7 mmHg diastolic.  		136411	17767	C101426	D017311
sildenafil	Amlodipine	9	9	false	none	Amlodipine    When sildenafil 100 mg oral was co-administered with amlodipine, 5 mg or 10 mg oral, to hypertensive patients, the mean additional reduction on supine blood pressure was 8 mmHg systolic and 7 mmHg diastolic.  		136411	17767	C101426	D017311
sildenafil	doxazosin	4	4	false	none	In drug-drug interaction studies, sildenafil (25 mg, 50 mg, or 100 mg) and the alpha-blocker doxazosin (4 mg or 8 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy.  		136411	49276	C101426	49276
sildenafil	doxazosin	4	4	false	none	In drug-drug interaction studies, sildenafil (25 mg, 50 mg, or 100 mg) and the alpha-blocker doxazosin (4 mg or 8 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy.  		136411	49276	C101426	49276
